Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-02-24Clinical Trial Update: Extension Study for 2993-112 [Phase 3]
This update notes the completion of the extension study for AstraZeneca's Phase 3 trial 2993-112 in Type 2 diabetes mellitus.
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin [Phase 3]
Phase 3 trial evaluating the safety and efficacy of exenatide in patients with Type 2 Diabetes Mellitus using metformin or sulfonylureas wit…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 study evaluating exenatide as monotherapy for glucose control in adults with Type 2 diabetes mellitus; the trial status is completed…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes [Phase 2]
A Phase 2 trial evaluated the effect of exenatide on a 24-hour blood glucose profile compared with placebo in patients with Type 2 Diabetes …
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy [Phase 3]
Phase 3 study assessing the efficacy and safety of LMF237 in adults with Type 2 diabetes inadequately controlled on vildagliptin monotherapy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin [Phase 3]
Phase 3 trial evaluating safety and efficacy of Exenatide in adults with Type 2 Diabetes Mellitus using thiazolidinediones, with or without …
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes [Phase 2]
This is a Phase 2 clinical trial update evaluating LY2148568 for glucose control, safety, and tolerability in Japanese patients with Type 2 …
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Safety and Efficacy of Exenatide as Monotherapy [Phase 3]
This document reports the completion of a Phase 3 trial evaluating exenatide as monotherapy for type 2 diabetes, detailing its safety and ef…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy [Phase 3]
Phase 3 clinical trial comparing Exenatide with insulin glargine in Type 2 diabetes patients for whom insulin therapy is appropriate. The st…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus [Phase 2]
A Phase 2 study evaluating the pharmacokinetics, pharmacodynamics, and tolerability of Exenatide in adolescent subjects with Type 2 Diabetes…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents [Phase 2]
A Phase 2 safety study evaluating substituting exenatide for insulin in patients with type 2 diabetes who use insulin and oral antidiabetic …
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects [Phase 1]
Phase 1 study in healthy male volunteers comparing three concentrations of NN9535 has completed, providing initial pharmacokinetic and safet…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes [Phase 3]
A Phase 3 study evaluating the effect of twice-daily exenatide on glucose control and safety/tolerability in adults with Type 2 diabetes has…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes [Phase 1]
Phase 1 study evaluating the effect of exenatide on gastric emptying in subjects with Type 2 Diabetes Mellitus has completed.
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes [Phase 3]
A Phase 3 trial evaluating whether taking exenatide before breakfast and dinner is equivalent to taking it before lunch and dinner in adults…
-
FDA approval · 2015-02-23FDA Approved: IRBESARTAN — Original Application (AvKARE)
FDA approved AvKARE's original generic application for irbesartan (IRBESARTAN). Irbesartan is used to treat hypertension.
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus [Phase 2]
A Phase 2 clinical trial update evaluating AC2993 for glucose control and its safety/tolerability in patients with Type 2 diabetes mellitus.
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination [Phase 3]
Phase 3 trial evaluating AC2993 for improvement of glucose control and safety in adults with Type 2 diabetes treated with metformin, sulfony…
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
This Clinical Trial Update reports results from a completed study in Italian patients with Type 2 diabetes assessing beta-cell dysfunction a…
-
CLINICAL_TRIALS trial_result · 2015-02-19Clinical Trial Update: The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients [Phase 1]
This entry provides a Phase 1 update on SHR3824, covering pharmacokinetic/pharmacodynamic characteristics as well as preliminary efficacy, s…
-
CLINICAL_TRIALS trial_result · 2015-02-19Clinical Trial Update: The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients [Phase 1]
Phase 1 clinical trial update evaluating SHR3824 in combination with metformin for Type 2 Diabetes Mellitus. The study assesses PK/PD, preli…
-
FDA approval · 2015-02-18FDA Approved: GLYBURIDE AND METFORMIN HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application from Aurobindo Pharma Limited for a glyburide and metformin hydrochloride combination tablet. The pr…
-
FDA approval · 2015-02-18FDA Approved: GLYBURIDE-METFORMIN HYDROCHLORIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Glyburide-Metformin Hydrochloride from Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals Inc.,…
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes [NA]
A completed clinical trial investigated how GLP-1 signaling and liraglutide influence brain satiety and reward circuits and feeding behavior…
-
FDA approval · 2015-02-18FDA Approved: GLYBURIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic diabetes drug glyburide from Heritage Pharmaceuticals (Avet) under ANDA 090937.